<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00879905</url>
  </required_header>
  <id_info>
    <org_study_id>CHSP990A2101</org_study_id>
    <secondary_id>2008-006440-19</secondary_id>
    <nct_id>NCT00879905</nct_id>
  </id_info>
  <brief_title>A Study of HSP990 Administered by Mouth in Adult Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase I Dose Escalation, Multi-center, Open-label Study of HSP990 Administered Orally in Adult Patients With Advanced Solid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will study the safety, tolerability and metabolism of a drug called HSP990 when&#xD;
      given by mouth once a week or twice weekly to subjects with advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose of HSP990 in patients treated once weekly or twice weekly</measure>
    <time_frame>At the end of the dose escalation phase of the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>True DLT rate</measure>
    <time_frame>At the end of the 1st 4 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary Efficacy</measure>
    <time_frame>Every 2 months (or 8 weeks, which equals 2 treatment cycles)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug metabolism in Humans, PK, PD</measure>
    <time_frame>every 4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Advanced Solid Malignancies</condition>
  <arm_group>
    <arm_group_label>once weekly dosing schedule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>twice weekly dosing schedule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HSP990</intervention_name>
    <arm_group_label>once weekly dosing schedule</arm_group_label>
    <arm_group_label>twice weekly dosing schedule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with histologically confirmed, advanced malignant solid tumors whose disease&#xD;
             has progressed on standard therapy or for whom no standard therapy exists&#xD;
&#xD;
          2. All patients must have at least one measurable lesion as defined by RECIST. Irradiated&#xD;
             lesions are only evaluable for disease progression&#xD;
&#xD;
          3. All patients must have documented progressive disease before entering the study&#xD;
&#xD;
          4. Age ≥ 18 years&#xD;
&#xD;
          5. World Health Organization (WHO) Performance Status ≤ 2&#xD;
&#xD;
          6. Life expectancy of ≥ 12 weeks&#xD;
&#xD;
          7. Patients must have the certain laboratory values&#xD;
&#xD;
          8. Patients able and willing to swallow capsules&#xD;
&#xD;
          9. Ability to understand the patient information and informed consent form and comply&#xD;
             with the protocol&#xD;
&#xD;
         10. Signed and dated written informed consent is available&#xD;
&#xD;
         11. Only for patients enrolled at MTD: willing to provide a fresh pre-dose and post-dose&#xD;
             tumor biopsy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with present or history of CNS metastasis.&#xD;
&#xD;
          2. Prior treatment with any Hsp90 or HDAC inhibitor compound.&#xD;
&#xD;
          3. Patients who have not recovered from side effects of previous systemic anticancer&#xD;
             therapy to &lt; CTCAE Grade 2 prior to the first dose&#xD;
&#xD;
          4. Patients identified to be &quot;poor or intermediate CYP2C9 metabolizers&quot;&#xD;
&#xD;
          5. Patients who received systemic anti-cancer treatment prior to the first dose of HSP990&#xD;
             within the following time frames:&#xD;
&#xD;
               -  Patients who have received cyclical chemotherapy within a period of time that is&#xD;
                  shorter than the cycle length used for that treatment (e.g., 6 weeks for&#xD;
                  nitrosourea, mitomycin-C) prior to starting study drug or who have not recovered&#xD;
                  from the side effects of such therapy&#xD;
&#xD;
               -  Patients who have received biologic therapy (e.g., antibodies) within a period of&#xD;
                  time that is ≤ 4 weeks prior to starting study drug or who have not recovered&#xD;
                  from the side effects of such therapy&#xD;
&#xD;
               -  Patients who have been treated with a continuous or intermittent small molecule&#xD;
                  therapeutic within a period of time that is ≤ 5 t1/2 or ≤ 4 weeks (whichever is&#xD;
                  shorter) prior to starting study drug or who have not recovered from the side&#xD;
                  effects of such therapy&#xD;
&#xD;
               -  Patients who have received any other investigational agents within a period of&#xD;
                  time that is ≤ 5 t1/2 or less than the cycle length used for that treatment or ≤&#xD;
                  4 weeks (whichever is shorter) prior to starting study drug or who have not&#xD;
                  recovered from the side effects of such therapy&#xD;
&#xD;
               -  Patients who have received wide field radiotherapy (including therapeutic&#xD;
                  radioisotopes such as strontium 89) ≤ 4 weeks or limited field radiation for&#xD;
                  palliation ≤ 2 weeks prior to starting study drug or who have not recovered from&#xD;
                  side effects of such therapy.&#xD;
&#xD;
               -  Patients who have undergone major surgery ≤ 2 weeks prior to starting study drug&#xD;
                  or who have not recovered from side effects of such therapy&#xD;
&#xD;
          6. Treatment with therapeutic doses of sodium warfarin (Coumadin).&#xD;
&#xD;
          7. Patients using medications that are CYP2C9 inhibitors and/or medications known to have&#xD;
             QT prolongation effect and cannot be switched or discontinued to an alternative drug&#xD;
             prior to commencing HSP990 dosing.&#xD;
&#xD;
          8. Unresolved diarrhea ≥ CTCAE grade 2&#xD;
&#xD;
          9. Patients who do not have either an archival tumor sample available or readily&#xD;
             obtainable in the course of the study or are unwilling to have a fresh tumor sample&#xD;
             collected at baseline.&#xD;
&#xD;
         10. Pregnant or lactating women.&#xD;
&#xD;
         11. Fertile women of childbearing potential (WCBP) not using adequate contraception&#xD;
             (abstinence, oral contraceptives, intrauterine device or barrier method of&#xD;
             contraception in conjunction with spermicidal jelly or surgically sterile). Male&#xD;
             patients whose partners are WCBP, not using adequate contraception.&#xD;
&#xD;
         12. Acute or chronic liver disease.&#xD;
&#xD;
         13. Acute or chronic renal disease.&#xD;
&#xD;
         14. Impairment of gastrointestinal (GI) function or GI disease that may significantly&#xD;
             alter the absorption of HSP990&#xD;
&#xD;
         15. Other concurrent severe and/or uncontrolled medical conditions (e.g., uncontrolled&#xD;
             diabetes, active or uncontrolled infection) that could cause unacceptable safety risks&#xD;
             or compromise compliance with the protocol.&#xD;
&#xD;
         16. Known diagnosis of HIV infection (HIV testing is not mandatory).&#xD;
&#xD;
         17. Patients with a history of another primary malignancy that is currently clinically&#xD;
             significant or currently requires active intervention&#xD;
&#xD;
         18. Cardiac exclusion criteria:&#xD;
&#xD;
               -  History (or family history) of long QT syndrome.&#xD;
&#xD;
               -  Mean QTcF ≥ 480 msec on screening ECG&#xD;
&#xD;
               -  History of clinically manifest ischemic heart disease including myocardial&#xD;
                  infarction, or unstable angina ≤ 3 months prior to study start.&#xD;
&#xD;
               -  Left ventricular (LV) dysfunction (LVEF ≤ 45%) by MUGA or ECHO&#xD;
&#xD;
               -  Clinically significant ECG abnormalities including one or more of the following:&#xD;
                  left bundle branch block (LBBB), right bundle branch block (RBBB) with left&#xD;
                  anterior hemiblock (LAHB), or 3rd degree AV block.&#xD;
&#xD;
               -  History or presence of atrial fibrillation, atrial flutter or ventricular&#xD;
                  arrhythmias including ventricular tachycardia or Torsades de Pointes.&#xD;
&#xD;
               -  Clinically significant resting bradycardia (&lt; 50 beats per minute).&#xD;
&#xD;
               -  Patients who are currently receiving treatment with any medication which has a&#xD;
                  relative risk or prolonging the QTcF interval or inducing Torsades de Pointes (as&#xD;
                  listed in Post-text supplement 2) and cannot be switched or discontinued to an&#xD;
                  alternative drug prior to commencing HSP990 dosing.&#xD;
&#xD;
               -  Obligate use of a cardiac pacemaker.&#xD;
&#xD;
               -  Other clinically significant heart disease (e.g., congestive heart failure,&#xD;
                  uncontrolled hypertension, history of labile hypertension, or history of poor&#xD;
                  compliance with an antihypertensive regimen)&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toulouse Cedex 3</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Spain</country>
  </location_countries>
  <removed_countries>
    <country>Hong Kong</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=9063</url>
    <description>Results for CHSP990A2101 can be found on the Novartis Clinical Trials Results Website</description>
  </link>
  <verification_date>October 2012</verification_date>
  <study_first_submitted>April 9, 2009</study_first_submitted>
  <study_first_submitted_qc>April 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2009</study_first_posted>
  <last_update_submitted>December 6, 2020</last_update_submitted>
  <last_update_submitted_qc>December 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase I</keyword>
  <keyword>Adults</keyword>
  <keyword>HSP990</keyword>
  <keyword>Advanced Solid Tumors</keyword>
  <keyword>Hsp90 inhibitor</keyword>
  <keyword>Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

